Recurring trauma nightmares are one of the most treatment-resistant symptoms of post-traumatic stress disorder, and until now no drug has been specifically approved to treat them. A multicenter, double-blind, randomized controlled trial published in Nature Medicine by researchers at Charité – Universitätsmedizin Berlin found that dronabinol, a prescription medication derived from THC, eliminated nightmares entirely for more than a third of patients — the strongest evidence yet that a cannabinoid can directly target this specific symptom.
A Ten-Week Trial Against Placebo
The trial enrolled 171 adults with PTSD who reported recurring, distressing nightmares tied to their trauma. Participants were randomly assigned to take either dronabinol, dosed nightly at 2.5 to 15 milligrams, or a placebo before bed for 10 weeks.
On a standard 0-to-8 nightmare burden scale combining frequency and intensity, the dronabinol group's scores dropped by an average of 3.7 points, compared to a 2.2-point drop in the placebo group — a meaningful gap given how difficult nightmare disorder has proven to treat with existing options. More than a third of patients on dronabinol reported their nightmares disappeared completely, and another 21% reported at least a 50% reduction in nightmare burden. Researchers also observed broader improvements in overall sleep quality among those taking the drug.
Why This Trial Is Different
Smaller and less rigorous studies have hinted that cannabinoids might ease PTSD nightmares — an open-label trial of nabilone found symptom reduction in most participants, and a small 2015 crossover trial in Canadian military personnel showed similar promise. But this is the first large-scale, multicenter, placebo-controlled trial to test a prescription cannabinoid specifically against nightmares in a general PTSD population, rather than a narrow subgroup.
Dronabinol itself isn't new — it's already FDA-approved in the United States for other indications, including chemotherapy-induced nausea and appetite loss in HIV/AIDS patients — meaning physicians can prescribe it off-label for nightmares without waiting for a new approval process specific to PTSD.
An Important Limitation
The researchers were careful to note what the drug did not do: it targeted nightmares specifically, but did not meaningfully improve other core PTSD symptoms, including the depression that frequently accompanies the disorder. That distinction matters clinically — dronabinol appears to be a tool for one especially disruptive symptom rather than a treatment for PTSD as a whole, and patients would likely still need additional therapy or medication to address the broader condition.
What This Means for Patients
For the estimated majority of PTSD patients who experience recurring nightmares — a symptom linked to poor sleep, daytime dysfunction, and increased suicide risk — this trial offers the first robust evidence that a specific, prescribable medication can meaningfully reduce or eliminate them. Because dronabinol is already approved and available, patients whose nightmares haven't responded to existing approaches like prazosin or trauma-focused therapy now have trial-backed evidence to discuss an off-label option with their physician. It is not a substitute for comprehensive PTSD treatment, but as a targeted intervention for one of the condition's most sleep-disrupting symptoms, it fills a gap that has had no dedicated pharmacological answer until now.
